Foresee Pharmaceuticals Co (ROCO:6576) Short-Term Debt: NT$0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6576 Foresee Pharmaceuticals Co Ltd ROCO:6576
57 GF Score
Price NT$79.50
GF Value NT$84.22
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Foresee Pharmaceuticals Co Short-Term Debt?

Foresee Pharmaceuticals Co ROCO:6576 57 Short-Term Debt is NT$0.0 Mil as of Mar. 2026. GuruFocus rates ROCO:6576 with a GF Score™ of 57/100 and a GF Value™ of NT$84.22 (Fairly Valued). The stock has 10 warning signs investors should review.

Foresee Pharmaceuticals Co's Short-Term Debt for the quarter that ended in Mar. 2026 was NT$0.0 Mil.

Foresee Pharmaceuticals Co's quarterly Short-Term Debt declined from Sep. 2025 (NT$255.0 Mil) to Dec. 2025 (NT$197.0 Mil) and declined from Dec. 2025 (NT$197.0 Mil) to Mar. 2026 (NT$0.0 Mil).

Foresee Pharmaceuticals Co's annual Short-Term Debt declined from Dec. 2023 (NT$200.0 Mil) to Dec. 2024 (NT$155.0 Mil) but then increased from Dec. 2024 (NT$155.0 Mil) to Dec. 2025 (NT$197.0 Mil).

Foresee Pharmaceuticals Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Foresee Pharmaceuticals Co Short-Term Debt Related Terms

Foresee Pharmaceuticals Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Foresee Pharmaceuticals Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foresee Pharmaceuticals Co Short-Term Debt Chart

Foresee Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 200.00 155.00 197.00

Foresee Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.00 155.00 255.00 197.00 0.00
ROCO:6576
57GF Score
Foresee Pharmaceuticals Co Ltd ROCO:6576
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$0.0 Mil mean?
Foresee Pharmaceuticals Co (ROCO:6576) has a Short-Term Debt of NT$0.0 Mil as of Mar. 2026.
Is Foresee Pharmaceuticals Co's Short-Term Debt too high?
Foresee Pharmaceuticals Co's current Short-Term Debt is NT$0.0 Mil. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's Short-Term Debt compare to ZTS?
Foresee Pharmaceuticals Co's Short-Term Debt of NT$0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Foresee Pharmaceuticals Co's current Short-Term Debt is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Fairly Valued. The stock's GF Value™ is NT$84.22, compared to a current price of NT$79.50 — trading 5.6% below its estimated fair value. The current Short-Term Debt is NT$0.0 Mil. Foresee Pharmaceuticals Co's overall GF Score™ is 57/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current Short-Term Debt is NT$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?

Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$79.50 is trading 5.6% below its estimated GF Value™ of NT$84.22. GuruFocus considers Foresee Pharmaceuticals Co to be Fairly Valued.

Key valuation signals for ROCO:6576:

  • Short-Term Debt: NT$0.0 Mil
  • GF Value™: NT$84.22 vs. price of NT$79.50 (5.6% below fair value)
  • GF Score™: 57/100 with 10 warning signs

No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Foresee Pharmaceuticals Co Business Description

Address No. 19-3, Sanchong Road, 9th Floor-2, Nangang District, Taipei, TWN, 115
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
57GF Score

Get the complete analysis for ROCO:6576

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$79.50
Price
NT$84.22
GF Value